Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Tetrahydrozoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.97 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrozoline SCHEMBL23496614 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL29393067 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL9296922 | 0.99 | CYP2D6 (0.97) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL30292036 | 0.98 | ADRA2A (1.00) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL34760 | 0.98 | ADRA2A (1.00) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL29603648 | 0.98 | ADRA2A (1.00) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL871337 | 0.97 | ADRA1A (0.97) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL1140101 | 0.91 | ADRA1A (0.85) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| SCHEMBL10930958 | 0.89 | CYP2D6 (0.83) | CYP2D6MEN1ALDH1A1BLMKMT2A | |
| Tetrahydrozoline SCHEMBL1512892 | 0.88 | ADRA1A (0.81) | CYP2D6MEN1ALDH1A1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5039 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12490932-B2 | Ophthalmic drug delivery | EYENOVIA, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-20240164708-A1 | OPHTHALMIC DRUG DELIVERY | HYPERION DEFI, INC. | 2024-05-23 | — | — | US | claimed |
| CN-117729945-A | Fragrance composition, method of making and articles comprising the same | 埃克苏德公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| US-20230124969-A1 | OPHTHALMIC FORMULATION COMPRISING N-[5-(AMINOSULFONYL)-4-METHYL-1,3- THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE HEMIHYDRATE | AIC316 GMBH (DE) | 2023-04-20 | — | — | US | claimed |
| US-20220395221-A1 | OPHTHALMIC DRUG DELIVERY | HYPERION DEFI, INC. | 2022-12-15 | — | — | US | claimed |
| EP-4096632-A1 | OPHTHALMIC FORMULATION COMPRISING N-[5-(AMINOSULFONYL)-4-METHYL-1,3- THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE HEMIHYDRATE | AiCuris GmbH & Co. KG (DE) | 2022-12-07 | — | — | EP | claimed |
| US-20220031625-A1 | OPHTHALMIC COMPOSITIONS FOR DELIVERING MEIBUM-LIKE MATERIALS | ALTAIRE PHARMACEUTICALS, INC. | 2022-02-03 | — | — | US | claimed |
| CN-112190542-B | Aqueous in-situ gel ophthalmic preparation for treating xerophthalmia | 艾威药业(珠海)有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113891697-A | Device and method for flow control of ophthalmic formulations | 特清公司 | 2022-01-04 | — | — | CN | claimed |
| EP-0694310-A1 | REVERSIBLE, THERMALLY GELLING WATER-BASE MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1996-01-31 | — | — | EP | claimed |
| WO-1994005330-A1 | NASAL SPRAY PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-17 | — | — | WO | claimed |
| WO-1993024149-A1 | PHARMACEUTICAL POWDER COMPOSITION CONTAINING NON-IONIC CELLULOSE ETHER DERIVATIVE AND A CHITIN-DERIVED POLYMER | THE PROCTER & GAMBLE COMPANY (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0571671-A1 | A Pharmaceutical composition in powder form | THE PROCTER & GAMBLE COMPANY (US) | 1993-12-01 | — | — | EP | claimed |
| EP-0550615-A1 | DRUG DELIVERY VEHICLES SUSPENDED IN NONAQUEOUS PERFLUORINATED CARRIER. | ALLERGAN INC (US) | 1993-07-14 | — | — | EP | claimed |
| US-5188826-A | Used for dry eye application, consists of crosslinked acrylic acid polymer, one or more demulcents and vasoconstrictors; administered to eye in drop or gel form and releases water | INSITE VISION INCORPORATED (US) | 1993-02-23 | — | — | US | claimed |
| WO-1992005770-A1 | DRUG DELIVERY VEHICLES SUSPENDED IN NONAQUEOUS PERFLUORINATED CARRIER | ALLERGAN, INC. (US) | 1992-04-16 | — | — | WO | claimed |
| WO-1992000707-A1 | TOPICAL OPHTHALMIC SUSPENSIONS | INSITE VISION INCORPORATED (US) | 1992-01-23 | — | — | WO | claimed |
| US-4603131-A | Method and composition for treating and preventing irritation of the mucous membranes of the nose | BERNSTEIN, JOEL E. | 1986-07-29 | — | — | US | claimed |
| EP-0093373-A1 | Method and composition for treating and preventing irritation of the mucous membranes of the nose | Bernstein, Joel E. (US) | 1983-11-09 | — | — | EP | claimed |